Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2Withdrawn 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 272Leukemia 194Precursor Cell Lymphoblastic Leukemia-Lymphoma 131Lymphoma 108Congenital Abnormalities 68Myelodysplastic Syndromes 63Leukemia, Myelomonocytic, Acute 60Leukemia, Monocytic, Acute 58Leukemia, Erythroblastic, Acute 56Leukemia, Megakaryoblastic, Acute 54Lymphoma, Non-Hodgkin 51Burkitt Lymphoma 44Lymphoma, Mantle-Cell 42Lymphoma, Large B-Cell, Diffuse 41Lymphoma, Follicular 33Leukemia, Myelomonocytic, Chronic 28Anemia, Refractory, with Excess of Blasts 27Hodgkin Disease 26Recurrence 25Lymphoma, Large-Cell, Immunoblastic 25Leukemia, Lymphocytic, Chronic, B-Cell 25Blast Crisis 24Leukemia, Eosinophilic, Acute 19Leukemia, Myelogenous, Chronic, BCR-ABL Positive 18Myeloproliferative Disorders 17Leukemia, Basophilic, Acute 17Lymphoma, B-Cell, Marginal Zone 16Leukemia, Promyelocytic, Acute 16Leukemia, Myeloid, Chronic-Phase 15Leukemia, Myeloid, Accelerated Phase 14

Interventions

Brentuximab Vedotin 17fludarabine 9Cyclophosphamide 9dacetuzumab 6Lenalidomide 6Bortezomib 6ruxolitinib 5fludarabine phosphate 5Rituximab 5Melphalan 5Dexamethasone 4Busulfan 4lintuzumab 3Whole-Body Irradiation 3Mycophenolic Acid 3Imatinib Mesylate 3Granulocyte Colony-Stimulating Factor 3Doxorubicin 3Calcium Dobesilate 3Azacitidine 3vosaroxin 2spartalizumab 2ponatinib 2nilotinib 2Vincristine 2Thiotepa 2Tacrolimus 2Sugars 2Stem Cell Transplantation 2Rifampin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Hematologic Diseases × Cytarabine × Clear all
NCT01191801 2018-08-22

VALOR

Sunesis Pharmaceuticals

Phase 3 Completed
711 enrolled 15 charts
Other hematologic neoplasm

Hematologic Diseases, Leukemia, Neoplasms, Leukemia, Myeloid, Acute

NCT00528333 2015-01-07

A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML

Seagen Inc.

Phase 2 Completed
211 enrolled
Other hematologic neoplasm

Hematologic Diseases, Leukemia, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡